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KRAS is the most frequently mutated oncogene in non-small cell lung cancer (NSCLC). However, the prognostic role of KRAS
mutation status in NSCLC still remains controversial. We hypothesize that the expression changes of genes affected by KRAS
mutation status will have the most prominent effect and could be used as a prognostic signature in lung cancer.
We divided NSCLC patients with mutation and RNA-seq data into KRAS mutated and wild type groups. Mann-Whitney test
was used to identify genes showing altered expression between these cohorts. Mean expression of the top five genes was
designated as a “transcriptomic fingerprint” of the mutation. We evaluated the effect of this signature on clinical outcome in
2,437 NSCLC patients using univariate and multivariate Cox regression analysis.
Mutation of KRAS was most common in adenocarcinoma. Mutation status and KRAS expression were not correlated to
prognosis. The transcriptomic fingerprint of KRAS include FOXRED2, KRAS, TOP1, PEX3 and ABL2. The KRAS signature had a
high prognostic power. Similar results were achieved when using the second and third set of strongest genes. Moreover, all
cutoff values delivered significant prognostic power (p< 0.01). The KRAS signature also remained significant (p< 0.01) in a
multivariate analysis including age, gender, smoking history and tumor stage.
We generated a “surrogate signature” of KRAS mutation status in NSCLC patients by computationally linking genotype and
gene expression. We show that secondary effects of a mutation can have a higher prognostic relevance than the primary
genetic alteration itself.
Despite advances in the last decade, lung cancer remains the
most lethal tumor in women and men still exceeding the
combined mortality of breast, prostate, colorectal and pancre-
atic cancers.1 Non-small cell lung cancer (NSCLC) accounts
for nearly 85% of all lung cancer cases and is further classi-
ﬁed into different subtypes including adenocarcinoma (AC),
squamous cell carcinoma and large cell carcinoma.2 Onco-
genic mutations not only enable tumor development but also
delineate new anticancer therapy targets.3 To date, ﬁve
molecularly targeted agents have been approved for the treat-
ment of NSCLC. Targeting the epidermal growth factor
receptor (EGFR) was the ﬁrst pioneer of personalized therapy
in lung cancer.4,5 EGFR kinase domain mutations are present
in about 20% of AC patients. Among others, exon 19 dele-
tion and point mutations in exon 18 and 21 deliver high sen-
sitivity to EGFR tyrosine kinase inhibitors (TKIs) erlotinib,6
geﬁtinib7 and afatinib.8 The EML4-ALK fusion gene is found
in 2–7% of AC patients9 and generally occurs independently
of other oncogenic drivers, including EGFR, KRAS or ERBB2
mutations.10 NSCLC patients carrying ALK rearrangements
have shown resistance to anti-EGFR TKIs but sensitivity to
ALK inhibitors comprising crizotinib and ceritinib.11 Upcom-
ing agents explored in preclinical and clinical studies target
KRAS, BRAF, ERBB2, PI3KC and translocations involving
RET, ROS and ampliﬁcation of c-MET.12
The RAS gene family includes KRAS, NRAS and HRAS
and encodes for plasma membrane-localized proteins with
intrinsic GTPase activity. RAS proteins serve as molecular
switches, regulating intracellular signal transduction pathways
in response to stimulation of cell surface receptors (targets
reviewed in Ref. 13). Mutations in KRAS, NRAS and HRAS
are commonly observed in various tumor types, including
NSCLC.14 The most frequently affected isoform is KRAS,
which is mutated in 25% of lung ACs.15 Interestingly, KRAS
mutations are more frequent in smokers and in Caucasians.
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In NSCLC, the vast majority of KRAS mutations involve
codons 12 or 13, with G12C, G12D and G12V mutations
being predominant, and are responsible for triggering the
constitutively active state of the enzyme.16
Mutations in KRAS are associated with an intrinsic
EGFR-TKI resistance.17 Considering the localization of KRAS
downstream of the EGF receptors, activating mutations of
KRAS render the entire signaling network triggered regard-
less of upstream inhibition. Therefore, KRAS is a negative
predictor for targeted therapy, and mutant patients will not
respond to administration of EGFR-TKIs.18 The correlation
between response and KRAS mutations status and resistance
against EGFR-TKIs in NSCLC has also been validated in
meta-analysis studies19 and is now listed in the NCCN guide-
lines (https://www.nccn.org/). KRAS is an idyllic predictive
biomarker—the predictive value is over 99%, the mutations
are in a conﬁned segment of the gene and we have a reason-
able biological hypothesis elucidating its role.
Targeted therapy of KRAS mutant lung cancer could be
based on the inhibition of main signaling pathways down-
stream of the active KRAS, including the RAF-MEK-ERK
and the PI3K-AKT-mTOR pathways. Preclinical results show
that the MEK1/2 inhibitor selumetinib signiﬁcantly sup-
pressed tumor growth in KRAS mutant NSCLC xenografts.20
In vivo combination of selumetinib with docetaxel improved
median PFS of NSCLC patients (5.3 vs. 2.1 months), never-
theless with more adverse events than docetaxel alone.21
Optimal treatment of KRAS mutant NSCLC patients remains
an open issue.
At the same time, it is unclear whether somatic mutations
of KRAS per se are related to poor survival and treatment
resistance. Although at ﬁrst a prognostic effect was suggested
in colon cancer,22 it was not possible to validate these results
in later studies for colon23 or lung cancer.24 Differences in
effect of KRAS mutations between Asian and non-Asian pop-
ulations was uncovered in a recent meta-analysis, indicating
that in Asian patients the KRAS mutations are a poor prog-
nostic factor.25
As a ﬁrst step of this study, we performed a literature sur-
vey to uncover the proportion of papers describing a correla-
tion between survival and KRAS status in NSCLC. The
absolute majority of studies investigating this issue utilize the
raw mutation status. Because of the crucial role of KRAS in
different cell signal transduction pathways, KRAS mutations
cannot solely affect the gene itself and the expression of
corresponding protein, but can also inﬂuence the expression
of other downstream genes. Here, we hypothesize that the
expression changes of these genes could be used as a surro-
gate marker of the KRAS mutation status. To evaluate this
hypothesis, we divided NSCLC patients into two cohorts—
those with a genetic alteration in KRAS gene and wild type—
identiﬁed the signature of genes showing altered expression
between these cohorts. Then, we evaluated the correlation of
this “transcriptomic ﬁngerprint” with clinical outcome.
Methods
Identifying studies evaluating the prognostic power of
KRAS
We performed a literature search in PubMed (http://www.
ncbi.nlm.nih.gov/pubmed) to identify studies assessing the
prognostic effect of somatic KRAS mutations in NSCLC
patients. In this, the keywords “lung cancer” and “KRAS
mutation” were used. We ﬁltered to include articles contain-
ing human samples and published in English between 2011
and 2015. We reduced our search results to those articles
where the somatic KRAS mutation status was determined.
The complete workﬂow of the literature survey is presented
in Figure 1a.
Somatic mutation data of NSCLC patients
The statistical analysis used three types of data: genotype
data containing somatic mutations and copy number varia-
tions (CNVs), RNA-seq gene expression and microarray gene
chip data.
Next generation sequencing data (exome sequencing and
RNA-seq data) for NSCLC patients including AC and squa-
mous cell lung carcinoma was downloaded from The Cancer
Genome Atlas of the National Cancer Institute (TCGA, http://
cancergenome.nih.gov)26,27 (Fig. 1b). We used the CGHub
repository (https://cghub.ucsc.edu/) to download the aligned
TCGA samples using the download client software GeneTor-
rent (version 3.8.5) for both tumor and normal samples.
Identiﬁcation of mutations from exome sequencing data
was performed by MuTect algorithm using default parame-
ters.28,29 Hard ﬁlters were applied to ﬁlter out somatic muta-
tions that had <203 coverage, and <4 altered reads. We used
the human reference genomes GRCh37, GRCh37-lite and
HG19 for mutation calling. To annotate the identiﬁed muta-
tions we used the dbSNP (bulid 139) and COSMIC (version 68)
databases.30 We applied the SNPeff v3.5 program to functional-
ly annotate VCF ﬁles generated byMuTect.31
What’s new?
As many as one-quarter of patients with lung adenocarcinoma (AC), a form of non-small cell lung cancer (NSCLC), exhibit
tumor-associated mutations in KRAS. Whether KRAS mutation status and expression are correlated to prognosis, however,
remains unclear. In this study, a surrogate signature of KRAS mutation status was generated for NSCLC by relating genotype
to gene-expression signature. The approach led to the identification of a significant correlation between overall survival in
lung AC and the transcriptomic fingerprint of somatic KRAS mutations. Three genes strongly influenced by KRAS mutation may
be relevant to the search for novel NSCLC drug targets.
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We ﬁltered the CNV data obtained from the TCGA
repository according to two parameters: at least 10 probes
had to be present at a position with a segment mean above
0.2 for ampliﬁcation, and under 20.2 for deletions. For the
annotation of the ﬁltered segments, we used the Human
Gene Sets GTF annotation ﬁle downloaded from the Ensem-
ble database of the Human Genome version GRCh37.
Processing of RNA-seq data
We used the preprocessed (level 3) RNA-seq data generated
by the Illumina HiSeq 2000 RNA Sequencing Version 2 plat-
form. RNA-seq data was normalized in R v3.2.3 statistical
environment (http://www.r-project.org) using DESeq Biocon-
ductor library using a negative binomial distribution.32 We
decided to use DESeq normalization because of its capability
to maintain a realistic false-positive rate when compared to
other normalization methods for RNA-seq data.
Gene chip database
We used a previously established lung cancer microarray
database33 that contains 2,437 samples measured using Affy-
metrix HGU133 microarrays (1,800 samples from GEO,
http://www.ncbi.nlm.nih.gov/geo/), 504 samples from CaAr-
ray project, http://cabig.cancer.gov/ and 133 samples from
the TCGA repository). Gene chips were normalized with the
MAS5 algorithm by the Affy Bioconductor library. Array
quality control was performed as described previously.34 For
each gene, we selected the most reliable probe set using
JetSet.35
To enable comparison of RNA-seq and gene-chip data,
both databases were ﬁltered to include only those genes,
which were present on both transcriptomic platforms. This
matched gene list contained all together 11,500 genes. To
avoid bias due to background noise, genes with a mean
expression below 100 (MAS5 normalized expression value)
were excluded from further analyses.
Statistical analysis pipeline
Statistical computations were performed in the R v3.2.3 sta-
tistical environment. The ﬁrst step of the analysis was split-
ting of RNA-seq samples into two cohorts based on the
alteration (somatic mutations or CNVs) of KRAS gene. Then
we applied Mann-Whitney-Wilcoxon test to identify genes
differentially expressed between the mutated and wild type
cohorts. The analysis was restricted to patients with a coding
mutation in KRAS. We also calculated the fold change value
for each gene. In a nonparametric analysis, the mean expres-
sion of the top ﬁve genes whose expression was signiﬁcantly
associated with genotype alteration of KRAS was designated
as the “KRAS-signature.”
The following step of the analysis was executed using the
gene chip data. The gene chip data was used because there
the sample number was a magnitude higher than those with
RNA-seq data. In addition, more clinical data was available
for these patients. We examined the correlation between the
KRAS surrogate signature and overall survival (OS) using
Cox proportional hazards regression and by plotting Kaplan-
Meier survival plots. Cox regression analysis was performed
using the “survival” R package v2.38 downloaded from
CRAN (http://CRAN.project.org/package5 survival). Kaplan-
Meier plots were generated applying the “survplot” R package
v0.0.7 (http://www.cbs.dtu.dk/eklund/survplot). Fulﬁlment
of the proportional hazards assumption necessary for the
Cox regression was validated by employing the “coxph” R
function. Prevalence of mutations in further cancer genes
among KRAS wild type and mutant patients was compared
using a v2 test. Statistical signiﬁcance was set at p< 0.05.
Results
Literature survey of KRAS mutations in lung cancer
The search in PubMed resulted in 1,403 hits, of which 741
were published between 2011 and 2016, were English and
utilized human samples (search was performed on the 31th
Figure 1. Analysis workflow for the literature survey (a) and for the database setup (b).
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January 2016). Of these, KRAS was sequenced in 221 studies
(Supporting Information Table S1). Effect of KRAS mutation
status on survival was examined in 138 articles. In these,
gene mutations correlated with survival in 38 studies, with
clinicopathological parameters, including smoking history,
resistance to treatment, tumor growth in 76 studies. Mutation
status was not prognostic at all in 24 studies (Fig. 1a). Corre-
lation of KRAS mutations with prognosis according to differ-
ent NSCLC subtypes is shown in Table 1. We have to note
that some studies did not mention any lung cancer subtype
or contained more than one.
Database construction
The TCGA repository holds 1,026 NSCLC patients—includ-
ing 522 AC and 504 SCC samples. The distribution of AC
and SCC was similar in the TCGA and the microarray data-
bases. OS was available for 967 patients with a median follow
up of 8.68 months. When performing survival analysis to
inspect the correlation between clinico-pathological parame-
ters and clinical outcome, there were signiﬁcant correlations
between the OS and tumor size (p5 0.0001), lymph node
status (p5 2.03E–06) and metastasis (p5 0.03).
Microarray data was available for 2,437 patients. Gene
expression was determined using three different gene chip
platforms (GPL96, GPL570 and GPL3921). OS data was
accessible for 2,002 patients and the median follow up was
41.6 months. Survival differences were signiﬁcant in patients
stratiﬁed by tumor size (p< 1E–16), lymph node status
(p< 1E–16) and metastasis (p5 0.003).
Neither KRAS mutations nor KRAS gene expression have a
prognostic power
First, we examined the impact of KRAS mutations per se on
OS. In the AC subgroup, including 60 patients harboring any
type of KRAS somatic mutation, KRAS mutation status was
not signiﬁcantly correlated with OS (HR5 1.02; 95%
CI5 0.5–1.9; p5 0.95; Fig. 2a). In SCC cohort there was
only one patient harboring a KRAS mutation. For this rea-
son, all the subsequent analyses were performed for AC
patients only.
We obtained similar results when investigating the effect
of KRAS gene expression on OS using the gene chip database
(Fig. 2b). Lack of any correlation between survival and
Table 1. Studies evaluating the impact of KRAS mutations in lung cancer (n5138)
All studies
n (%)
Do not mention
any NSCLC
subtype n (%)
AC n
(%)
SCC n
(%)
LCC n
(%)
LCN n
(%)
SC n
(%)
ASCC n
(%)
KRAS mutations correlat-
ed with survival
38 (28%) 17 (12%) 17 (12%) 2 (1%) 2 (1%) – – –
KRAS mutations correlat-
ed with other clinico-
pathological features
76 (55%) 27 (20%) 37 (27%) 4 (3%) 3 (2%) 2 (1%) 1 (1%) 2 (1%)
KRAS mutations did not
have a significant
effect
24 (17%) 13 (9%) 9 (7%) 1 (1%) 1 (1%) – 1 (1%) 1 (1%)
NSCLC: non-small cell lung cancer; AC: adenocarcinoma; SCC: squamous cell carcinoma; LCC: large cell carcinoma; LCN: large cell neuroendocrine
carcinoma; SC: sarcomatoid carcinoma; ASCC: adenosquamous carcinoma.
For detailed information about each study see Supporting Information Table S1.
Figure 2. KRAS gene per se has no correlation to survival in NSCLC. Analysis of the effect of KRAS mutation (a) and expression (b) on surviv-
al in NSCLC AC patients. When investigating different cutoff values across all patients (c), none of the threshold values between the lower
and upper quartile of expression reached statistical significance. The strongest achieved p values is marked by a red circle in (c). [Color fig-
ure can be viewed at wileyonlinelibrary.com]
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prognostic power can be observed when plotting a graph of
the achieved p values vs. all the potential cutoff values (Fig.
2c).
Similar non-signiﬁcant results were obtained when investigat-
ing the correlation between survival and KRAS expression using
the RNA-seq database (Supporting Information Figure S1).
The KRAS mutation surrogate signature has a significant
effect on survival
Each of the 60 patients had a coding mutation in KRAS. Sev-
en of these also had a noncoding mutation. The ﬁve strongest
genes correlation to KRAS status in the Mann-Whitney test
include the FOXRED2, PEX3, KRAS, TOP1 and ABL2 genes
(Table 2). The mean expression of these genes was used as a
surrogate signature of KRAS mutation status in the gene chip
database. When using the median expression as a cutoff, we
achieved high association with OS (HR5 2.4; 95% CI5 1.9–
3.2; p5 1.24E–12; Fig. 3a). When computing the p values
achieved in the Cox regression across all possible cutoff val-
ues between the lower and upper quartiles of expression, all
the p values remained highly signiﬁcant (Fig. 3b).
Quality control
To validate the approach of running a nonparametric analysis
using the ﬁve strongest genes, we have also run the analysis
using the second and the third set of ﬁve best genes associat-
ed with KRAS mutation (Supporting Information Table 2).
Both these additional signatures delivered very similar results
to the set of the ﬁrst ﬁve genes: the second set reached
HR5 1.9; 95% CI5 1.5–2.5 (at p5 4.7E-08) and the third
set delivered a HR5 2.5; 95% CI5 1.9–3.2 (at p5 4.4E-14;
Figs. 3c and 3d).
The main strength of our analysis was the use of an
RNA-seq dataset in the training cohort and then the use of a
gene chip dataset for the validation cohort. Since different
technology platforms can measure expression of the same
gene with different sensitivity, speciﬁcity and dynamic range,
a strong correlation between these platforms is an important
issue for the reliability of our analysis. There were 130
NSCLC samples published in TCGA with simultaneous
RNA-seq and gene chip measurement. When comparing the
mean expression of surrogate signature of KRAS mutations
in these, the two platforms delivered a highly signiﬁcant cor-
relation (p5 6.4E-11, Spearman rank corr. coeff.5 0.53; Sup-
porting Information Figure S2).
When comparing the prevalence of mutations in KRAS
wild and in KRAS mutated patients for all Cosmic Cancer
Consensus Genes, only one gene was identiﬁed at a false dis-
covery rate below 10%, namely KRAS itself. The following
strongest genes (listed in Supporting Information Table S3.)
had a very low prevalence (for example FOXO1 was mutated
in only one, and FUBP1 in only two patients in the KRAS
wild type cohort—the exclusion of patients with these muta-
tions did not changed the KRAS surrogate signature).
Table 2. Nonparametric transcriptomic fingerprint of top five genes correlated to KRAS mutation status (A), KRAS amplification (B) and KRAS
deletion (C)
p–Values Fold change
Mean expression
in mutants
Mean expression
in wild
A)
FOXRED2 1.14E–06 0.62 944 1530
KRAS 6.31E–06 1.29 4472 3462
TOP1 7.06E–06 1.29 10272 7979
PEX3 1.51E–05 0.77 499 647
ABL2 1.81E–05 1.22 2534 2077
B)
KRAS 1.55E–09 1.94 6553 3379
ETNK1 5.29E–06 1.57 5865 3740
FAM60A 8.00E–06 1.77 7491 4243
TMEM185B 8.33E–06 1.29 1623 1258
CLEC11A 1.73E–05 0.55 298 544
C)
HSDL2 5.91E–05 1.64 3923 2398
GAK 1.06E–04 0.63 3132 4982
YARS2 1.44E-04 0.61 517 846
MCOLN1 1.50E-04 0.63 733 1155
CMAS 1.65E-04 0.59 1095 1862
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Impact of KRAS amplification and deletion driven signature
on survival in AC
We further analyzed the prognostic roles of surrogate signa-
tures of KRAS ampliﬁcation and deletion. KRAS ampliﬁca-
tions were found in 30 patients and deletions found in 12
patients. The KRAS ampliﬁcations related signature includes
KRAS, ETNK1, FAM60A, TMEM185B and CLEC11A genes
(Table 2). Nevertheless, the KRAS ampliﬁcation signature
was not correlated with OS as presented on Supporting Infor-
mation Figure S3A (HR5 0.91; 95% CI5 0.7–1.2; p5 0.45).
KRAS deletions associated with the expression of HSDL2,
GAK, YARS2, MCOLN1 and CMAS (Table 2). The average
expression of these genes was signiﬁcantly associated with OS
(HR5 2.3; 95% CI5 1.8–2.9; p5 1.8E–11, Supporting Infor-
mation Figure S3B).
Multivariate analysis
In a multivariate analysis of OS including surrogate signature
for KRAS mutation, age, gender, smoking history and tumor
stage, only the KRAS signature (p5 0.01), age (p5 0.01) and
stage (p5 5E-07) emerged as signiﬁcant factors. When per-
forming the same analysis for KRAS deletion, only age
(p5 0.01) and stage (p5 3E-07) remained signiﬁcant.
Discussion
We have assessed the correlation between KRAS and OS in
lung cancer. Different types of data including mutation status
and gene expression were assessed at ﬁrst, but these did not
have a signiﬁcant prognostic power. These results are in line
with the outcome of the literature survey, as no correlation
to survival was observed in 72% of all studies with KRAS
sequencing performed in NSCLC.
KRAS mutations cannot solely affect the gene itself and
the expression of the corresponding protein, but can also
inﬂuence the expression of other downstream genes involved
in crucial pathways regulating cell growth, differentiation and
apoptosis. Thus, the different expression of these genes in
KRAS-mutant tumors might have a more prominent role in
affecting patient’s clinical outcomes. Having multiple levels of
data for the same patients opens a window of opportunity
for a two-step analysis: ﬁrst, a genome wide transcriptomic
analysis across all genes was performed to identify genes
affected by a KRAS mutation. In the second step, the stron-
gest genes were combined into a “surrogate signature” of
KRAS mutation status, and the correlation between this
expression based signature and clinical outcome was comput-
ed. Interestingly, the surrogate signature had a dramatic effect
on patient’s outcome.
Figure 3. The surrogate signature of KRAS mutation status has a high prognostic power. Signature comprising the mean expression of the
top five genes (a). When investigating different cutoff values between the lower and upper quartiles of expression for the surrogate signa-
ture, every cutoff value achieved high significance (b). Similar results were achieved when using the second (c) and the third (d) set of five
strongest genes. [Color figure can be viewed at wileyonlinelibrary.com]
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In our analysis, we set up a signature encompassing the
top ﬁve genes only. To validate this approach, we also evalu-
ated additional signatures comprising the second and third
sets of strongest genes and both these settings delivered simi-
lar signiﬁcance. One might wonder how a limited signature
of ﬁve genes can provide such robust information in the case
of mutant KRAS. The most probable reason for this is the
extreme high level of interconnections in the signaling net-
work resulting in a concordant expression change across
multiple downstream genes.13 We have to note that the sur-
rogate signature was highly signiﬁcant regardless of the used
cutoff value and remained signiﬁcant in a multivariate analy-
sis including clinicopathological parameters.
This approach has an additional advantage: to link a
sequence variation to clinical outcome we would need thou-
sands of patients with sufﬁcient follow up data. However, in
the TCGA dataset the median follow up of NSCLC patients is
merely 8.68 months, therefore preventing a reliable direct test-
ing of the prognostic impact. At the same time, available gene
chip datasets comprising NSCLC samples have ﬁve times longer
follow up times and extensive clinical annotations.
The top ﬁve genes affected by a somatic KRAS mutation
include FOXRED2, KRAS, TOP1, PEX3 and ABL2. Of these,
three genes were already associated with tumor development
besides KRAS. TOP1 (topoisomerase 1) plays a crucial role
in DNA replication and maintaining genome stability by reg-
ulating the supercoiling state of DNA. TOP1 is also the cellu-
lar target for irinotecan, an agent approved for advanced or
metastatic NSCLC.36 Higher expression of TOP1 in KRAS
mutant patients and correlation to survival suggests that
TOP1 inhibitors might have increased beneﬁt when adminis-
tered to treat patients with a KRAS mutant tumor.
The ABL2 gene is a member of the Abelson family of
non-receptor tyrosine protein kinases.37 These kinases are
involved in controlling cell growth, survival, invasion, adhe-
sion and migration.38 Oncogenic activation of the ABL kin-
ases is most known in Philadelphia-positive (Ph1) human
leukemias where the generated BCR-ABL1 fusion protein has
a constitutive tyrosine kinase activity. Currently, ABL kinases
are targeted by several FDA-approved agents including imati-
nib and dasatinib to treat patients with BCR-ABL1-positive
leukemias.39 ABL2 ampliﬁcation is prevalent among ABL
alterations, which has been detected in invasive lung and
breast carcinomas.40,41 Similar to TOP1, the expression of
ABL2 was also increased in KRAS mutant samples. Thus,
agents targeting ABL kinases might have a beneﬁcial effect in
patients harboring a KRAS genetic alteration.
The FOXRED2 (FAD-dependent oxidoreductase domain
containing 2) gene is also highly expressed in human tumors
including NSCLC, colorectal cancer and breast cancer.42
Hypoxia has recently been associated with oncogenesis in
multiple tumors and it has been suggested that administra-
tion of HAPs (hypoxia-activated prodrugs) may bring poten-
tial therapeutic beneﬁt in some tumors.43 HAPs, including
the nitro aromatic compounds TH-30244 and PR-10445 are
currently in clinical development. HAPs are metabolized to
cytotoxic DNA damaging agents via enzyme-catalyzed reduc-
tive reactions. FOXRED2, as a HAP reductase, is enzymati-
cally capable to activate HAPs; therefore it contributes to
prodrug activation in some human tumors.42 Our results sug-
gest KRAS mutation as a negative biomarker for HAPs–
response might be lower in tumors with a KRAS mutation.
The signature includes ﬁve genes only and these could be
easily measured by RT-PCR in a tumor sample. The genes
are linked to a set of agents (TOP1 inhibitors, ABL kinase
inhibitors and HAPs), which could deliver different efﬁciency
in KRAS mutated and wild type patients. A successful valida-
tion of these drugs in a future clinical trial would open the
possibility to identify patients eligible for a new set of agents
depending on the interconnection between gene expression
and mutation status in other key genes as well.
In a similar setup, we also determined the effect of surro-
gate signatures related to KRAS ampliﬁcations and deletions
on OS in lung cancer. As expected, loss of KRAS was a good
prognostic marker.
We have to note some limitations of our analysis. First,
the literature survey and the results of mutation calling both
show that KRAS mutations are overwhelmingly more fre-
quent in AC compared with other NSCLC subtypes. For this
reason, we had to limit our analysis and consequently or
conclusions to AC of the lung. A second limitation is the
exclusion of additional effects on transcription like epigenetic
regulation—the same mutation with or without a methylation
event might result in different transcriptional outcome.
Unfortunately, methylation data was not available for the
investigated patients.
In summary, here we generated a “surrogate signature” of
KRAS mutation status in lung AC patients by computational-
ly connecting genotype to an extended gene expression signa-
ture. We show that three out of the top ﬁve genes inﬂuenced
by a KRAS mutation could also have a direct pharmacologi-
cal implication. We used the surrogate signature in a large
and well annotated gene chip database to test its prognostic
signiﬁcance and found that the transcriptomic ﬁngerprint of
somatic KRAS mutations had a highly signiﬁcant correlation
with OS in lung AC. Our results emphasize the prominence
of KRAS and prove that secondary effects can have a superi-
or prognostic relevance compared to the primary genetic
alteration.
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